Psychedelics for the Menopause Transition with Alicia Bigelow, ND
Psychedelic Medicine Podcast with Dr. Lynn Marie Morski
Release Date: 12/17/2025
Psychedelics and Neurodiversity with Dr. WaiFung Tsang, DClinPsy
Psychedelic Medicine Podcast with Dr. Lynn Marie Morski
In this episode, Dr. WaiFung Tsang, DClinPsy joins to discuss the intersection of psychedelics and neurodiversity. Dr. Tsang is a clinical research psychologist from Hong Kong, musician, and student of Shipibo curanderismo. He is the co-founder of Onaya, an organisation dedicated to bridging Indigenous tradition and Western science, and research advisor for psychedelic veteran charity Heroic Hearts Project. In this conversation, Dr. Tsang explores the emerging intersection of psychedelics and neurodiversity, reframing neurodivergence as a context-dependent spectrum shaped by biology, culture,...
info_outline
Spravato: The Accessible Psychedelic Medicine with Amy Della Rocca, PMHNP
Psychedelic Medicine Podcast with Dr. Lynn Marie Morski
In this episode Amy Della Rocca, PMHNP joins to discuss Spravato, the FDA-approved prescription esketamine nasal spray, and its place in the field of psychedelic medicine. Amy is a psychiatric nurse practitioner and the Clinical Director of Marpa, a Spravato treatment center in New York. In this conversation, Amy offers a grounded and practical look at Spravato as one of the most accessible forms of psychedelic medicine currently available, especially for patients with treatment-resistant depression who may be priced out of intravenous or intramuscular ketamine treatments. She explains how...
info_outline
Low-Dose Ketamine for Chronic Pain: A Biopsychosocial Approach with Michelle Weiner, DO, MPH
Psychedelic Medicine Podcast with Dr. Lynn Marie Morski
In this episode, Michelle Weiner, DO, MPH returns to share her expertise on low-dose ketamine for chronic pain. Dr. Weiner is double board-certified in Interventional Pain Medicine, Physical Medicine, and Rehabilitation. She is founder of Neuropain Health delivering personalized integrative care treating the root cause of pain and suffering, both physical and emotional, using a multidisciplinary biopsychosocial approach with many years of clinical experience with ketamine-assisted therapy. In this conversation, Dr. Weiner reframes chronic pain as more than a symptom of tissue damage,...
info_outline
Ayahuasca for PTSD with Dr. Simon Ruffell MBChB, MRCPsych, PhD
Psychedelic Medicine Podcast with Dr. Lynn Marie Morski
In this episode Dr. Simon Ruffell joins to discuss the research on ayahuasca for PTSD. Dr. Ruffell is a psychiatrist, researcher, and student of curanderismo (Amazonian shamanism) working at the intersection of Western psychiatry, traditional plant medicine, and Indigenous knowledge systems. He is Executive Director of Onaya, Lecturer in Psychology and Psychedelics at the University of Exeter, and Chief Medical Officer of MINDS, with a focus on integrative and relational approaches to healing and consciousness. In this conversation, Dr. Ruffell explores the emerging research on ayahuasca as a...
info_outline
Impacts of Social Inequality on Psychedelic Healing with Sean Viña, PhD
Psychedelic Medicine Podcast with Dr. Lynn Marie Morski
In this episode, Dr. Sean M. Viña joins to discuss the ways that social inequality can impact psychedelic healing. Dr. Viña is a sociologist with a PhD from Indiana University whose research focuses on psychedelics and mental health, and social inequality. In this conversation, Dr. Viña explains that while psychedelics are often framed as transformative treatments, their benefits appear unevenly distributed and frequently constrained by structural factors such as income inequality, education, stigma, caregiving burden, segregation, and social isolation. The discussion highlights how...
info_outline
Psychedelics and Religion with Hunt Priest, MDiv
Psychedelic Medicine Podcast with Dr. Lynn Marie Morski
In this episode, Hunt Priest joins to discuss the intersection of psychedelic experiences and religion. Hunt is the founder of Ligare: A Christian Psychedelic Society and was a participant in the Johns Hopkins/NYU Psilocybin Study for Religious Leaders in 2016. The epiphanies he had at Hopkins forever changed the trajectory of his work and led him to start Ligare in 2021. In this conversation, Hunt Priest reflects on how participating in the Johns Hopkins study reshaped his understanding of Christianity, embodiment, and spiritual experience. Drawing on his background as an Episcopal priest, he...
info_outline
Encore Episode: How Psychedelics Affect the Brain with Manesh Girn, PhD
Psychedelic Medicine Podcast with Dr. Lynn Marie Morski
In this encore episode of the Psychedelic Medicine Podcast, psychedelic science researcher and educator Dr. Manesh Girn discusses his studies investigating psychedelic brain action. Manesh earned PhD in neuroscience at McGill University and is an author on over a dozen peer-reviewed articles on psychedelics and related topics. He is also chief research officer at EntheoTech Bioscience and runs the YouTube channel the Psychedelic Scientist. In this conversation, Manesh discusses his recent article in Trends in Cognitive Sciences titled He explains the complexity science approach used...
info_outline
Which Psychedelic for Which Condition? with Will Van Derveer, MD
Psychedelic Medicine Podcast with Dr. Lynn Marie Morski
In this episode, Will Van Derveer, MD joins to unpack what we know about which psychedelic medicines are best suited to particular mental health conditions. Dr. Van Derveer has trained several thousand mental health professionals in psychedelic-assisted psychotherapy, provided ketamine assisted therapy to hundreds of people, and has staffed MDMA therapy trials with MAPS. His book, Psychedelic Therapy: A Revolutionary Approach to Restoring Your Mental Health and Reclaiming Your Life, will be published by Shambala in the spring of 2026. In this conversation, Dr. Van Derveer offers a...
info_outline
Psychedelics for the Menopause Transition with Alicia Bigelow, ND
Psychedelic Medicine Podcast with Dr. Lynn Marie Morski
In this episode, Alicia Bigelow, ND joins to discuss the potential of psychedelic medicine to support the menopause transition. Dr. Ali Bigelow is a naturopathic physician, ketamine provider and licensed psilocybin facilitator in Portland, OR. She leads individual and group retreats, enjoys incorporating live music into her sessions when desired, and is passionate about supporting those navigating life transitions, such as end of life and menopause, through her low dose group, Menomorphosis. Dr. Bigelow will be doing retreats in 2026 with Rise Up Journeys at In this conversation, Dr. Bigelow...
info_outline
Psychedelics as Catalysts for Human Agency with Matthew W. Johnson, PhD
Psychedelic Medicine Podcast with Dr. Lynn Marie Morski
In this episode, Matthew W. Johnson, PhD returns to discuss how psychedelics can be leveraged to catalyze human agency. Dr. Johnson has been at the forefront of psychedelic research for 21 years, having conducted seminal research on the effects of psilocybin on mystical experience, personality, and treatment of cancer distress, major depressive disorder, and tobacco addiction. His work with tobacco addiction received the first federal funding for a classic psychedelic in the modern era of research. In this conversation, Dr. Johnson explores psychedelics as powerful enhancers of human...
info_outlineIn this episode, Alicia Bigelow, ND joins to discuss the potential of psychedelic medicine to support the menopause transition. Dr. Ali Bigelow is a naturopathic physician, ketamine provider and licensed psilocybin facilitator in Portland, OR. She leads individual and group retreats, enjoys incorporating live music into her sessions when desired, and is passionate about supporting those navigating life transitions, such as end of life and menopause, through her low dose group, Menomorphosis. Dr. Bigelow will be doing retreats in 2026 with Rise Up Journeys at RiseUpJourneys.com
In this conversation, Dr. Bigelow explores the emerging intersection between psychedelics and the menopausal transition, framing perimenopause and menopause as profound neuroendocrine, psychological, and existential shifts rather than merely clinical syndromes. She also discusses how hormonal changes—particularly declining estrogen—interact with serotonin, inflammation, and neuroplasticity, potentially shaping psychedelic experiences and outcomes. Throughout the discussion, Dr. Bigelow emphasizes the unique capacity of psychedelics to support self-actualization, identity reformation, and meaning-making during midlife, especially when combined with hormone therapy, intentional integration practices, and strong community support.
In this episode, you'll hear:
- Why perimenopause and menopause represent a major but under-recognized neurobiological life transition
- How estrogen, serotonin receptors, and psychedelics like psilocybin may interact in midlife
- What we know (and don’t yet know) about hormone replacement therapy and psychedelic efficacy
- The potential anti-inflammatory effects of psychedelics and their relevance to menopausal symptoms
- How ketamine may function differently from classic psychedelics during hormonal transitions
- Why psychedelics can support identity reorientation, self-actualization, and “not caring” in generative ways
- The critical role of community, creativity, and nervous system regulation in integration during midlife
Quotes:
“We don't honor and celebrate aging and elderhood overall in our culture. … What I do feel is really vital is that we gather and support each other in all of life's transitions, and [menopause has] not only been underrepresented, but also just under honored.” [3:29]
“As [estrogen] levels decrease, there's a decrease in serotonin receptors—which is the 5-HT2A receptor. And so that reduces our sensitivity to, and activity of serotonin. And psilocybin and LSD and other 5-HT2A agonists—they can enhance their receptors and the activity of those receptors.” [13:20]
“The understanding is that with [estrogen] hormone replacement therapy you would then, theoretically, see a replenishment of [serotonin] receptors, and then the psilocybin would have more ability to act on those receptors.” [15:37]
“Psilocybin—and psychedelics in general—and the menopausal transition are just really beautiful complements to each other and they become even more potent when used together.” [19:48]
Links: